Literature DB >> 27686391

Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease.

Jillian M Richmond1, Dinesh S Bangari2, Kingsley I Essien1, Sharif D Currimbhoy3, Joanna R Groom4, Amit G Pandya3, Michele E Youd2, Andrew D Luster5, John E Harris6.   

Abstract

Vitiligo is an autoimmune disease of the skin that results in the destruction of melanocytes and the clinical appearance of white spots. Disease pathogenesis depends on IFN-γ and IFN-γ-induced chemokines to promote T-cell recruitment to the epidermis where melanocytes reside. The skin is a complex organ, with a variety of resident cell types. We sought to better define the microenvironment and distinct cellular contributions during autoimmunity in vitiligo, and we found that the epidermis is a chemokine-high niche in both a mouse model and human vitiligo. Analysis of chemokine expression in mouse skin showed that CXCL9 and CXCL10 expression strongly correlate with disease activity, whereas CXCL10 alone correlates with severity, supporting them as potential biomarkers for following disease progression. Further studies in both our mouse model and human patients showed that keratinocytes were the major chemokine producers throughout the course of disease, and functional studies using a conditional signal transducer and activator of transcription (STAT)-1 knockout mouse showed that IFN-γ signaling in keratinocytes was critical for disease progression and proper autoreactive T-cell homing to the epidermis. In contrast, epidermal immune cell populations including endogenous T cells, Langerhans cells, and γδ T cells were not required. These results have important clinical implications, because topical therapies that target IFN-γ signaling in keratinocytes could be safe and effective new treatments, and skin expression of these chemokines could be used to monitor disease activity and treatment responses.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27686391      PMCID: PMC5258673          DOI: 10.1016/j.jid.2016.09.016

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  30 in total

1.  Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-gamma receptor complex following activation by IFN-gamma.

Authors:  J Larkin; H M Johnson; P S Subramaniam
Journal:  J Interferon Cytokine Res       Date:  2000-06       Impact factor: 2.607

2.  Two-Photon deep tissue ex vivo imaging of mouse dermal and subcutaneous structures.

Authors:  P So; H Kim; I Kochevar
Journal:  Opt Express       Date:  1998-10-26       Impact factor: 3.894

Review 3.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

Review 4.  Vitiligo.

Authors:  Khaled Ezzedine; Viktoria Eleftheriadou; Maxine Whitton; Nanja van Geel
Journal:  Lancet       Date:  2015-01-15       Impact factor: 79.321

5.  Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface.

Authors:  Patrice Nancy; Elisa Tagliani; Chin-Siean Tay; Patrik Asp; David E Levy; Adrian Erlebacher
Journal:  Science       Date:  2012-06-08       Impact factor: 47.728

Review 6.  Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease.

Authors:  Noah P Zimmerman; Rebecca A Vongsa; Michael K Wendt; Michael B Dwinell
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

Review 7.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

8.  Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients.

Authors:  Claire Regazzetti; Florence Joly; Carine Marty; Michel Rivier; Bruno Mehul; Pascale Reiniche; Carine Mounier; Yves Rival; David Piwnica; Marine Cavalié; Bérengère Chignon-Sicard; Robert Ballotti; Johannes Voegel; Thierry Passeron
Journal:  J Invest Dermatol       Date:  2015-08-31       Impact factor: 8.551

9.  A Long Noncoding RNA lincRNA-EPS Acts as a Transcriptional Brake to Restrain Inflammation.

Authors:  Maninjay K Atianand; Wenqian Hu; Ansuman T Satpathy; Ying Shen; Emiliano P Ricci; Juan R Alvarez-Dominguez; Ankit Bhatta; Stefan A Schattgen; Jason D McGowan; Juliana Blin; Joerg E Braun; Pallavi Gandhi; Melissa J Moore; Howard Y Chang; Harvey F Lodish; Daniel R Caffrey; Katherine A Fitzgerald
Journal:  Cell       Date:  2016-06-16       Impact factor: 41.582

10.  A vaccine strategy that protects against genital herpes by establishing local memory T cells.

Authors:  Haina Shin; Akiko Iwasaki
Journal:  Nature       Date:  2012-10-17       Impact factor: 49.962

View more
  43 in total

1.  Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation.

Authors:  Purvi Mande; Bahar Zirak; Wei-Che Ko; Keyon Taravati; Karen L Bride; Tia Y Brodeur; April Deng; Karen Dresser; Zhaozhao Jiang; Rachel Ettinger; Katherine A Fitzgerald; Michael D Rosenblum; John E Harris; Ann Marshak-Rothstein
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

Review 2.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 3.  The Role of Memory CD8+ T Cells in Vitiligo.

Authors:  Rebecca L Riding; John E Harris
Journal:  J Immunol       Date:  2019-07-01       Impact factor: 5.422

4.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

Review 5.  [Systemic treatment of vitiligo : Balance and current developments].

Authors:  M Meurer; P Ceric-Dehdari
Journal:  Hautarzt       Date:  2017-11       Impact factor: 0.751

6.  Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.

Authors:  James P Strassner; Mehdi Rashighi; Maggi Ahmed Refat; Jillian M Richmond; John E Harris
Journal:  J Am Acad Dermatol       Date:  2017-03-01       Impact factor: 11.527

7.  Mouse Model for Human Vitiligo.

Authors:  Rebecca L Riding; Jillian M Richmond; John E Harris
Journal:  Curr Protoc Immunol       Date:  2018-09-25

8.  Treatment of Severe Hailey-Hailey Disease With Apremilast.

Authors:  Julie Kieffer; Florence Le Duff; Henri Montaudié; Christine Chiaverini; Jean-Philippe Lacour; Thierry Passeron
Journal:  JAMA Dermatol       Date:  2018-12-01       Impact factor: 10.282

9.  Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Mehdi Rashighi; Priti Agarwal; Madhuri Garg; Kingsley I Essien; Lila S Pell; John E Harris
Journal:  J Invest Dermatol       Date:  2018-11-10       Impact factor: 8.551

10.  Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Lucio Zapata; Madhuri Garg; Rebecca L Riding; Maggi A Refat; Xueli Fan; Vincent Azzolino; Andrea Tovar-Garza; Naoya Tsurushita; Amit G Pandya; J Yun Tso; John E Harris
Journal:  Sci Transl Med       Date:  2018-07-18       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.